Amniocentesis Needle Market Size, Share & Industry Analysis, By Size (Smaller Than 100 mm, 100 to 150 mm, and Larger Than 150 mm), By Procedure (Amniocentesis Procedures, Amnioreduction Procedures, Amnioinfusion Procedures, and Others), By End-user (Hospitals, Diagnostic Centers, and Others), and Regional Forecast, 2026-2034

The global amniocentesis needle market size was valued at USD 174.4 million in 2025. The market is projected to grow from USD 181.3 million in 2026 to USD 254.2 million by 2034, exhibiting a CAGR of 4.3% during the forecast period.

An amniocentesis needle is a long, thin needle used in prenatal testing to withdraw a small sample of amniotic fluid from the uterus of pregnant women. This fluid is crucial to detect potential genetic abnormalities, chromosomal conditions, and other health issues in the fetus. Moreover, the procedure is guided by an ultrasound image to ensure safe insertion of the needle into the amniotic sac. The growth is attributed to the increasing demand for prenatal diagnostics, driven by standard regulations and recommendations for prenatal testing.

Furthermore, the market is dominated by major players, including CooperSurgical, Inc., ICU Medical, Inc., Medline Industries, LP, Cook, and others. These players are expanding their presence into emerging regions to gain a significant market share globally.

MARKET DYNAMICS

MARKET DRIVERS:

Rising Incidence of Chronic Diseases and Genetic Disorders to Drive Market Growth

Over the past few years, there has been a significant rise in the incidence of chronic diseases and genetic disorders, including Down syndrome and neural tube defects. This is expected to fuel the need for accurate prenatal diagnosis.

• For instance, according to the data published by the Centers for Disease Control and Prevention (CDC) in November 2024, around 5,700 babies are born with Down syndrome in the U.S. each year.

Moreover, there is also a surge in the rate of high-risk pregnancies, which is expected to fuel the demand for prenatal testing and screening for genetic abnormalities in the unborn. Such a scenario is anticipated to drive the global amniocentesis needle market growth.

MARKET RESTRAINTS:

Competition from Non-Invasive Prenatal Testing (NIPT) to Restrict Market Expansion

Despite the significant diagnostic accuracy through amniocentesis procedures, its invasive nature results in cramping or discomfort after the procedure. Also, it further increases the risk of infection and miscarriage in rare conditions.

As a result, over the past few years, there has been a rising preference for safer alternatives such as the non-invasive prenatal testing (NIPT), which analyzes fetal DNA from maternal blood to detect genetic disorders. Additionally, the NIPT is highly applicable in early pregnancy, which is spurring its demand and threatening the adoption of amniocentesis procedures, thereby hampering market growth.

• For instance, according to data from ScienceDirect in December 2024, NIPT is an accurate and safe screening test that has decreased the need for invasive tests, including amniocentesis.

MARKET OPPORTUNITIES:

Expansion in Emerging Markets to Offer Lucrative Growth Opportunities

In recent years, there has been an increase in healthcare infrastructure, higher birth rates, and greater awareness of prenatal testing in emerging countries of the Asia Pacific and Latin America.

• For instance, according to data from World Population Review, India's birth rate is 15.8 births per 100 individuals in 2025.

Moreover, the government in these regions is organizing maternal health programs, which are contributing to an increase in the volume of genetic screening tests, such as amniocentesis, in these regions. This is offering significant opportunities for key players to expand their offerings in these regions, thereby supporting the overall product penetration, which is expected to fuel the market expansion.

MARKET CHALLENGES:

High Procedure Costs and Limited Accessibility to Challenge Market Growth

Globally, the amniocentesis procedure has relatively high costs, posing a major challenge for middle-income populations to undergo such procedures. Additionally, this cost barrier is limiting accessibility for populations in emerging markets with limited healthcare spending.

Moreover, this invasive procedure further demands the need for skilled healthcare professionals and suitable infrastructure. These factors are expected to restrict wider adoption in resource-limited settings and challenge overall market expansion.

• For instance, in August 2025, ValuePenguin reported that the cost of amniocentesis generally varies depending on the location where the procedure is performed, typically ranging from USD 1,000 to USD 7,200.

AMNIOCENTESIS NEEDLE MARKET TRENDS:

Technological Advancements in Needle Design and Imaging to Emerge as a Key Market Trend

Currently, there have been significant innovations including ultra-fine and echogenic needles with atraumatic tips. Additionally, improved ultrasound visibility is being achieved through several advancements in equipment, which enhance precision and reduce patient discomfort.

Moreover, the integration of AI-powered ultrasound guidance is improving accuracy in needle placement, reducing further risks such as discomfort and infection in pregnant women. This is expected to improve overall clinical outcomes, allowing for safer and more efficient procedures.

Download Free sample to learn more about this report.

Segmentation Analysis

By Size

High Significance of 100-150 mm Needle in Prenatal Testing to Segmental Growth

Based on the product segmentation, the market is classified as smaller than 100 mm, 100 to 150 mm, and larger than 150 mm.

To know how our report can help streamline your business, Speak to Analyst

The 100- to 150-mm segment accounted for the largest global amniocentesis needle market share in 2025. Needles within a 100-150 mm length are clinically optimal for safely reaching the amniotic cavity without excessive insertion depth, thereby reducing the risk of fetal injury or maternal discomfort, and further increasing their usage and driving the segment’s growth.

In addition, the smaller than 100 mm segment is projected to grow at a CAGR of 4.8% during the forecast period.

By Procedure 

High Volume of Amniocentesis Procedures to Drive Segment’s Growth

Based on procedure, the market is segmented into amniocentesis procedures, amnioreduction procedures, amnioinfusion procedures, and others.

By procedure, the amniocentesis procedures segment accounted for the largest share in 2025. The segment’s growth is attributed to high procedure volume compared to others, as amniocentesis is routinely recommended for prenatal genetic testing in at-risk pregnancies. Furthermore, the segment is expected to hold a 40.3% share in 2026.

• For instance, in October 2025, the Mayo Foundation for Medical Education and Research (MFMER) mentioned that genetic amniocentesis is performed between the 14th and 20th weeks of pregnancy.

In addition, the amnioreduction procedures segment is projected to grow at a CAGR of 4.5% during the forecast period.

By End-user

Higher Procedures Performed in Hospital Settings Globally Drive the Segment Growth

On the basis of end-user, the market is categorized into hospitals, diagnostic centers, clinics, and others.

In 2025, the global market was dominated by hospitals in terms of end-user. Hospitals are the primary centers for amniocentesis procedures, often performed in obstetric and prenatal care units under ultrasound guidance. As a result, the large number of hospitals globally is anticipated to favor the segment’s growth during the forecast period. Furthermore, the segment is set to hold 61.7% share in 2026.

• For instance, the American Hospital Association's (AHA) Hospital Statistics, 2025, stated that there are approximately 6,093 hospitals in the U.S.

In addition, the diagnostic centers segment is projected to grow at a CAGR of 4.4% during the forecast period.

Amniocentesis Needle Market Regional Outlook

By region, the market is classified into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To get more information on the regional analysis of this market, Download Free sample

NORTH AMERICA

North America accounted for the largest share in 2024, reaching at USD 53.0 million, and also maintained the leading share in 2025, with USD 55.0 million. The growth is attributed presence of major players and a large number of prenatal testing procedures in Canada and the U.S., further driving the demand for amniocentesis needles. In 2026, the U.S. market is projected to account for USD 57.1 million.

• For instance, according to the American Pregnancy Association’s data in 2025, around 200,000 amniocentesis procedures are performed in the U.S. each year.

EUROPE and ASIA PACIFIC

Europe and the Asia Pacific regions are expected to witness significant growth in the forthcoming years. The Europe is projected to record a growth rate of 4.9% during the forecast period and is the second-largest among all regions. Furthermore, the region is set to account for valuation of USD 50.7 billion by 2026. This growth is attributed to the increasing number of diagnostic centers in the region, which is leading to a high volume of cytogenetic amniocentesis procedures. Due to such factors, the U.K. is anticipated to reach the market size of USD 7.7 million, France to reach USD 7.3 million, and Germany to reach USD 9.0 million in 2026. Furthermore, the Asia Pacific is anticipated to record USD 49.2 million in 2026, accounting for the third-largest region in the market. In 2026, the India and China are both set to record USD 7.1 million and USD 13.3 million, respectively, in Asia Pacific.

LATIN AMERICA and MIDDLE EAST & AFRICA

During the projection period, the Latin America and Middle East & Africa are expected to showcase moderate market growth. In 2026, the Latin America market is set to reach a valuation of USD 12.5 million. The growth is mainly due to higher birth and screening rates, driven by increasing awareness in the region. The GCC in the Middle East & Africa, is expected to reach the market size of USD 6.2 million by 2026.

COMPETITIVE LANDSCAPE

Key Industry Players:

Focus on Extending Marketing Reach to Strengthen Position of Prominent Players

In 2025, including CooperSurgical, Inc., ICU Medical, Inc., Medline Industries, LP, and Cook, accounted for the largest global amniocentesis needle market share. These key players are expanding their reach in emerging countries through collaboration, partnerships, facility expansions, and other strategic initiatives.

Other prominent companies, including RI.MOS. SRL, Laboratoire CCD, and Medax are focused on increasing trade volumes and product diversification to enhance their position in the global market 

LIST OF KEY AMNIOCENTESIS NEEDLE MARKET COMPANIES PROFILED:

• Cook (U.S.)
• CooperSurgical, Inc. (U.S.)
• MOS. srl (Italy)
• Laboratoire CCD (France)
• Medax (Italy)
• BIOPSYBELL S.R.L. Società unipersonale (Italy)
• ICU Medical, Inc. (U.S.)
• Medline Industries, LP. (U.S.)
• Vigeo srl (Italy)

KEY INDUSTRY DEVELOPMENTS:

• June 2024: The Cooper Companies Inc. announced the acquisition of ZyMōt Fertility, a company specializing in sperm separation technology for assisted reproductive technology (ART), broadening CooperSurgical’s portfolio of fertility products and services. This acquisition further enhanced CooperSurgical’s capabilities in fertility solutions, supporting clinics globally with innovative technologies such as amniocentesis needles to improve reproductive outcomes through prenatal testing.
• November 2023: The Cooper Companies Inc. expanded its medical device portfolio by acquiring select Cook Medical assets focused on obstetrics, Doppler monitoring, and gynecology surgery for USD 300.0 million.
• June 2023: BD signed a definitive agreement to sell its surgical instrumentation platform to STERIS plc for USD 540 million.
• February 2022: The Cooper Companies Inc. announced its plans to acquire Cook Medical’s Reproductive Health business for approximately USD 875 million, aiming to expand its international fertility footprint and medical device portfolio.
• October 2022: Vigeo srl announced that it participated in MEDICA 2022, showcasing its innovative range of medical devices, including amniotic needles, biopsy, and surgical instruments designed to improve diagnostic precision and patient safety.

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation